0RV2 Stock Overview
Develops biological drugs for patients with disorders of the central nervous system in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
BioArctic AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 178.00 |
| 52 Week High | SEK 270.20 |
| 52 Week Low | SEK 137.90 |
| Beta | -0.71 |
| 1 Month Change | 8.14% |
| 3 Month Change | -19.02% |
| 1 Year Change | -12.57% |
| 3 Year Change | 137.77% |
| 5 Year Change | 150.62% |
| Change since IPO | 559.26% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0RV2 | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -8.2% | 2.1% | -0.3% |
| 1Y | -12.6% | -13.2% | -0.4% |
Return vs Industry: 0RV2 matched the UK Biotechs industry which returned -13.2% over the past year.
Return vs Market: 0RV2 underperformed the UK Market which returned -0.4% over the past year.
Price Volatility
| 0RV2 volatility | |
|---|---|
| 0RV2 Average Weekly Movement | 9.3% |
| Biotechs Industry Average Movement | 8.9% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in GB Market | 11.1% |
| 10% least volatile stocks in GB Market | 3.2% |
Stable Share Price: 0RV2's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0RV2's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 107 | Gunilla Osswald | www.bioarctic.se |
BioArctic AB (publ) develops biological drugs for patients with disorders of the central nervous system in Sweden. The company research and development of innovative biological drugs, such as antibodies, that address high unmet medical needs. Its therapeutic areas encompass neurodegenerative disorders, such as Alzheimer’s disease, Parkinson’s disease, and other CNS diseases.
BioArctic AB (publ) Fundamentals Summary
| 0RV2 fundamental statistics | |
|---|---|
| Market cap | SEK 15.78b |
| Earnings (TTM) | -SEK 177.08m |
| Revenue (TTM) | SEK 257.35m |
60.6x
P/S Ratio-88.1x
P/E RatioIs 0RV2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0RV2 income statement (TTM) | |
|---|---|
| Revenue | SEK 257.35m |
| Cost of Revenue | SEK 26.98m |
| Gross Profit | SEK 230.37m |
| Other Expenses | SEK 407.45m |
| Earnings | -SEK 177.08m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 21, 2025
| Earnings per share (EPS) | -2.00 |
| Gross Margin | 89.51% |
| Net Profit Margin | -68.81% |
| Debt/Equity Ratio | 0% |
How did 0RV2 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/12 18:10 |
| End of Day Share Price | 2025/05/12 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BioArctic AB (publ) is covered by 6 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kristofer Liljeberg-Svensson | Carnegie Investment Bank AB |
| Patrik Ling | DNB Markets |
| Rajan Sharma | Goldman Sachs |